BEAM News and Press, Beam Therapeutics Inc.

CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the first patient was treated with BEAM-302, an investigational in vivo base editing medicine designe...

MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting its optimized, closed and automated manufacturing process for its base-edited CD34+ hematopoietic ...

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, president of Beam, plans to participate in a fireside chat during the Jeffer...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report data highlighting the robust, closed and automated manufacturing process ...

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the R...

2024-05-07 06:35:53 ET More on Beam Therapeutics Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now Verve drops after pausing trial enrollments for lead asset Beam ...

Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Clinical Trial Authorisation (CTA) Application Cleared for the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Study to Initiate in First H...

2024-04-30 13:25:04 ET Summary CRISPR/Cas9 technology allows for precise editing of DNA, potentially treating human diseases by replacing entire genes. CRISPR Therapeutics has developed the first FDA-approved ex vivo CRISPR/Cas9 therapy, Casgevy, for sickle cell disease and transf...

2024-04-23 21:48:22 ET Summary Beam Therapeutics is a biotech firm focused on developing precision genetic treatments using base editing technology. The company has secured $675 million in upfront payments from agreements with Pfizer, Apellis, Verve, and Sana. Collaboration ag...